In Depth 24 Apr 2024
Overcoming toxicities: are IL-2 smart cytokines the next big thing?
A more advanced form of IL-2 cytokine therapy called IL-2 smart cytokines could overcome side effects, and shake up cancer care as we know it.
In Depth
- Latest Posts
In Depth 22 Apr 2024
The biggest private biotech investments in March 2024
The companies Mirador Therapeutics, Alumis, and Sionna Therapeutics bagged the biggest private biotech investments in March 2024.
In Depth 17 Apr 2024
Small but mighty: The role of small-molecule drugs in disease treatment
Find out more about small-molecule drugs, including how they work and what their advantages and disadvantages are.
In Depth 15 Apr 2024
Does the FDA need to tighten its grip on drug trials in the U.S.?
Studies suggest that the FDA has been less rigorous with its drug approval standards. We looked at the current state of the approval process.
In Depth 10 Apr 2024
Silencing genes to cure diseases: an in-depth look at siRNA
Delve into the promissing and dynamic sector of siRNA technology, with new drug approvals and advancements in delivery methods.
In Depth 8 Apr 2024
A wave of biotech layoffs: will the trend continue throughout 2024?
Thousands of jobs have been at risk over the past year due to mass layoffs by biotech companies across the globe.
ADVERTISEMENT
ADVERTISEMENT
In Depth 4 Apr 2024
Seven diseases CRISPR technology could cure
Here are some of the diseases that scientists aim to tackle using CRISPR technology, testing its possibilities and limits as a medical tool.
In Depth 3 Apr 2024
Hepatitis B: are we edging closer to a cure?
Find out whether we are closing in on a cure for hepatitis B – a virus affecting the liver that can cause acute and chronic disease.
In Depth 27 Mar 2024
Are new treatments for multiple sclerosis on the horizon?
As the wait for new multiple sclerosis treatments continue, here are some ongoing clinical trials that hold promise.
In Depth 25 Mar 2024
Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better?
Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy.
In Depth 21 Mar 2024
Biotech in France: What’s holding back progress and how to move forward?
Explore the latest insights from France Biotech’s ‘Panorama France HealthTech’ report, uncovering key insights of the French biotech sector.
In Depth 20 Mar 2024
Are molecular glues the key to undruggable targets?
As more biopharmas get sticky with molecular glue developers and venture capital interest grows, here is a review of the field.
ADVERTISEMENT
